<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidermodysplasia verruciformis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidermodysplasia verruciformis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidermodysplasia verruciformis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jordan S Orange, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H619572217">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidermodysplasia verruciformis (EV; MIM #226400, #618231, #618267, #305350) is a rare autosomal recessive skin disease characterized by an abnormally high susceptibility to infection with certain types of human papillomavirus (HPV) called EV-HPV, mostly belonging to the beta-HPV genus, that preferentially affect the skin [
         <a href="#rid1">
          1-7
         </a>
         ]. Patients have disseminated polymorphic lesions, including flat-topped, wart-like papules and tinea versicolor-like macules, predominantly on skin areas exposed to sunlight (
         <a class="graphic graphic_picture graphicRef102317 graphicRef102288" href="/z/d/graphic/102317.html" rel="external">
          picture 1A-B
         </a>
         ). In addition, patients with EV have an increased risk of developing nonmelanoma skin cancers, mainly cutaneous squamous cell carcinomas (SCCs), at an early age [
         <a href="#rid8">
          8-11
         </a>
         ].
        </p>
        <p>
         This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of EV and distinguish genetic EV from acquired EV, which occurs in the setting of immunodeficiency. WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome (MIM #193670) is a rare genetic immunodeficiency disorder that also may present with increased susceptibility to HPV infection and cancer risk. Therefore, WHIM syndrome is also discussed briefly here. The epidemiology, virology, and natural history of HPV infection are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8314.html" rel="external">
          "Human papillomavirus infections: Epidemiology and disease associations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">
          "Virology of human papillomavirus infections and the link to cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H320236839">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of EV is not known. A total of 501 patients have been described worldwide; most cases are sporadic, but there are several reports of familial cases [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H619572223">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of EV is incompletely understood. It is thought to result from a combination of genetic factors leading to a selective immunodeficiency, infection from EV-human papillomaviruses (HPVs), and exposure to ultraviolet (UV) radiation [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H619572229">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         EV is inherited in an autosomal recessive fashion in most of the described families. Autosomal dominant and X-linked inheritance (EDVX) have also been reported [
         <a href="#rid15">
          15,16
         </a>
         ]. Biallelic pathogenic variants in either
         <em>
          TMC6
         </em>
         or
         <em>
          TMC8
         </em>
         (also named
         <em>
          EVER1
         </em>
         and
         <em>
          EVER2
         </em>
         ) on chromosome 17q25.3 cause EV1 and EV2, respectively, and have been found in 36 patients from 22 families [
         <a href="#rid12">
          12,13,17-28
         </a>
         ]. All described variants are loss-of-function variants (nonsense, splice site, frameshift variant, exon deletion, or insertion of amino acids) and result in a lack of functional protein production [
         <a href="#rid29">
          29
         </a>
         ]. Variants in a third gene,
         <em>
          CIB1
         </em>
         located on chromosome 15q26.1, were identified as causative for EV3. Homozygous
         <em>
          CIB1
         </em>
         null variants were identified in 24 patients from six families [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Some patients with EV-like phenotypes do not have variants in
         <em>
          TMC6
         </em>
         ,
         <em>
          TMC8
         </em>
         , or
         <em>
          CIB1
         </em>
         . Variants in other genes involved in primary T cell and/or natural killer (NK) cell immunodeficiencies, including
         <em>
          RHOH
         </em>
         (EV4),
         <em>
          LCK
         </em>
         ,
         <em>
          IL7
         </em>
         (EV5),
         <em>
          MST1
         </em>
         ,
         <em>
          CORO1A
         </em>
         ,
         <em>
          RASGRP1
         </em>
         ,
         <em>
          CARMIL2
         </em>
         ,
         <em>
          DCLRE1C
         </em>
         ,
         <em>
          DOCK8
         </em>
         , and
         <em>
          TTC7A
         </em>
         , are reported in a limited number of patients with susceptibility to HPV types typically detected in patients with EV, indicating nonallelic heterogeneity of the disease [
         <a href="#rid28">
          28,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">
          "Severe combined immunodeficiency (SCID): Specific defects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3949.html" rel="external">
          "NK cell deficiency syndromes: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="local">
          'Immune system abnormalities'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H59702061">
         <span class="h2">
          Role of TMC6 and TMC8
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          TMC6
         </em>
         and
         <em>
          TMC8
         </em>
         belong to a larger gene group named transmembrane channel-like gene family, which consists of a group of highly conserved transmembrane proteins [
         <a href="#rid31">
          31
         </a>
         ]. Yeast two-hybrid screens and co-immunoprecipitation data suggest that both
         <em>
          TMC
         </em>
         genes form a complex with the zinc transporter ZnT-1 [
         <a href="#rid24">
          24
         </a>
         ]. This complex is located within the membrane of the endoplasmic reticulum [
         <a href="#rid32">
          32
         </a>
         ] and influences the zinc homeostasis in cells by decreasing Zn
         <sup>
          2+
         </sup>
         release from the endoplasmic reticulum [
         <a href="#rid24">
          24,33
         </a>
         ].
        </p>
        <p>
         TMC6 and TMC8 proteins are involved in EV-HPV persistence and oncogenicity. It is hypothesized that the Zn
         <sup>
          2+
         </sup>
         level controlled by the
         <em>
          TMC
         </em>
         /ZnT-1 complex leads to a reduced activity of transcription factors, which are essential for the replication of EV-HPV. Due to
         <em>
          TMC
         </em>
         /ZnT-1 complex disruption, transcription factors increase and enable EV-HPV replication, leading to the EV phenotype [
         <a href="#rid32">
          32
         </a>
         ]. However, an effect on free zinc levels has not been detected in patients with
         <em>
          TMC6
         </em>
         or
         <em>
          TMC8
         </em>
         deficiency [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="local">
          'Human papillomavirus infection'
         </a>
         below.)
        </p>
        <p>
         One study showed that
         <em>
          TMC8
         </em>
         supports tumor necrosis factor (TNF)-alpha-dependent apoptosis but prevents TNF-alpha-dependent NF-kB activation by interaction with TNF receptor-associated death domain protein (TRADD) [
         <a href="#rid34">
          34
         </a>
         ]. Epidermis samples of patients with EV revealed an overexpression of transforming growth factor-beta-1 and TNF-alpha compared with samples of non-EV patients [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3614228330">
         <span class="h2">
          Role of CIB1
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          CIB1
         </em>
         encodes the calcium- and integrin-binding protein 1, which is strongly expressed in human epidermis and hair follicles [
         <a href="#rid29">
          29
         </a>
         ]. Even though it is reported to modulate cell migration and influence focal adhesion formation, influences on migration could not be observed in
         <em>
          CIB1
         </em>
         -deficient keratinocytes from patients with EV.
        </p>
        <p>
         In
         <em>
          TMC6
         </em>
         - and
         <em>
          TMC8
         </em>
         -deficient cells derived from patients with EV, CIB1 is not expressed. In healthy cells it forms a complex with both TMCs [
         <a href="#rid29">
          29
         </a>
         ]. Similarly to TMC6 and TMC8, which in previous studies have been shown to interact with HPV16 E5 [
         <a href="#rid24">
          24
         </a>
         ], CIB1 interacts with beta-HPV5 E1 and HPV16 E2. These connections suggest the involvement of the TMC6-TMC8-CIB1 complex in the defense against mucosal and cutaneous HPVs.
        </p>
        <p class="headingAnchor" id="H59701863">
         <span class="h2">
          Immune system abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the number of CD4
         <sup>
          +
         </sup>
         and CD8
         <sup>
          +
         </sup>
         T cells in patients with EV appears to be normal, a significant increase in memory CD4
         <sup>
          +
         </sup>
         and effector memory CD8
         <sup>
          +
         </sup>
         T cells as well as an increase in skin-homing CD4
         <sup>
          +
         </sup>
         T cell subsets has been reported [
         <a href="#rid36">
          36
         </a>
         ]. Both
         <em>
          TMC6
         </em>
         and
         <em>
          TMC8
         </em>
         are expressed in the skin and abundantly in T cells. Lymphoblastoid cells or primary T cells from patients with EV have increased levels of Zn
         <sup>
          2+
         </sup>
         [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         An EV-like phenotype has been described in patients with primary T cell and/or NK cell immunodeficiencies due to pathogenic variants of
         <em>
          RHOH
         </em>
         (EV4),
         <em>
          LCK
         </em>
         ,
         <em>
          IL7
         </em>
         (EV5),
         <em>
          MST1
         </em>
         ,
         <em>
          CORO1A
         </em>
         ,
         <em>
          RASGRP1
         </em>
         ,
         <em>
          CARMIL2
         </em>
         ,
         <em>
          DCLRE1C
         </em>
         ,
         <em>
          DOCK8
         </em>
         , and
         <em>
          TTC7A
         </em>
         [
         <a href="#rid38">
          38
         </a>
         ]. These patients also have increased susceptibility to bacterial and viral infections, including non-EV-HPV types [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         A late-onset form of EV, named "acquired epidermodysplasia verruciformis," is reported in patients with acquired cell-mediated immunodeficiency (HIV-positive patients and immunosuppressive treatment in organ transplant recipients) [
         <a href="#rid39">
          39-41
         </a>
         ]. (See
         <a class="local">
          'Acquired epidermodysplasia verruciformis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H619572241">
         <span class="h2">
          Human papillomavirus infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection from EV-HPV typically occurs during infancy [
         <a href="#rid42">
          42
         </a>
         ]. Patients with EV are susceptible to skin infections by particular types of HPV predominantly belonging to the genus beta (EV-HPV), which are considered to be nonpathogenic to the general population (
         <a class="graphic graphic_table graphicRef102332" href="/z/d/graphic/102332.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid14">
          14,43
         </a>
         ]. In contrast to other HPVs, EV-HPVs do not integrate into the human genome and do not have the HPV gene
         <em>
          E5
         </em>
         , encoding a protein that interacts, among others, with the zinc transporter ZnT-1. It is hypothesized that due to the missing
         <em>
          E5
         </em>
         the general population is enabled to suppress the invasion of EV-HPV. Patients with EV are not able to eliminate EV-HPV-harboring keratinocytes due to impaired Zn
         <sup>
          2+
         </sup>
         homeostasis [
         <a href="#rid24">
          24,32
         </a>
         ]. (See
         <a class="local">
          'Role of TMC6 and TMC8'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H59701806">
         <span class="h2">
          Skin cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Over 60 percent of patients with EV develop cutaneous squamous cell carcinoma (SCC), including SCC in situ (Bowen's disease), at an early age. Basal cell carcinomas and keratoacanthomas have also been reported [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Cutaneous SCCs arise almost exclusively in sun-exposed skin areas, and approximately 90 percent harbor EV-HPV type 5 or type 8, both expressing the oncoproteins E6 and E7 [
         <a href="#rid45">
          45
         </a>
         ]. However, the E6 and E7 proteins of most EV-HPVs have less transforming potential than E6 and E7 proteins of high-risk genital alpha-type HPVs (HPV16 and HPV18) [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">
          "Virology of human papillomavirus infections and the link to cancer"
         </a>
         .)
        </p>
        <p>
         These observations suggest that multiple factors are involved in the pathogenesis of cutaneous SCC in patients with EV, including direct damage of keratinocyte deoxyribonucleic acid (DNA) from UV radiation, inhibition of ultraviolet B (UVB)-induced keratinocyte apoptosis by HPV, activation of HPV promotors by UVB [
         <a href="#rid47">
          47
         </a>
         ], and UV-induced local immunosuppression [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H619572253">
         <span class="h1">
          PATHOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H619572260">
         <span class="h2">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathology of EV-lesions, also called EV-plane warts, demonstrates basket-weave hyperkeratosis, mild acanthosis, and vacuolated cells in the upper epidermis (
         <a class="graphic graphic_picture graphicRef102289" href="/z/d/graphic/102289.html" rel="external">
          picture 2
         </a>
         ). The nuclei can be pyknotic and may be surrounded by clear halos. The cytoplasm of affected cells stains pale blue and contains numerous round basophilic keratohyalin granules.
        </p>
        <p class="headingAnchor" id="H619572266">
         <span class="h2">
          Human papillomavirus detection
         </span>
         <span class="headingEndMark">
          —
         </span>
         EV-human papillomavirus (HPV) types can be detected in all patients with EV in lesional skin and in plucked eyebrow hairs by polymerase chain reaction and direct sequencing. (See
         <a class="medical medical_review" href="/z/d/html/8314.html" rel="external">
          "Human papillomavirus infections: Epidemiology and disease associations", section on 'Detection of HPV'
         </a>
         .)
        </p>
        <p>
         Multiple HPV types, including some alpha-types with uncertain correlation with EV, are usually present in the same patient (
         <a class="graphic graphic_table graphicRef102332" href="/z/d/graphic/102332.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid48">
          48-50
         </a>
         ]. Approximately 90 percent of cutaneous squamous cell carcinomas (SCCs) occurring in patients with EV harbor HPV types 5 or 8.
        </p>
        <p class="headingAnchor" id="H619572272">
         <span class="h2">
          Immunohistochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         An analysis of specific epidermal markers (KRT1, 10, 14, 16, 4, involucrin, filaggrin, and E-cadherin) in EV lesions demonstrated diminished expression of K1 and K10, which were replaced by K14, reflecting immaturity and lack of differentiation in the abnormal epidermis [
         <a href="#rid51">
          51
         </a>
         ]. In addition, K16 and K4, normally not found in the differentiated epidermis, as well as involucrin were overexpressed in the spinous layer, suggesting disturbed proliferation and differentiation of the epidermal cells. Such alterations could be induced by the
         <em>
          E7
         </em>
         gene of some HPV types [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H320237064">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Persons with EV usually develop multiple polymorphic skin lesions during early infancy or childhood. In many patients, the clinical appearance of the lesions does not immediately suggest verruca. Lesions may present as flat-topped, papular lesions similar to verrucae planae on the extremities (
         <a class="graphic graphic_picture graphicRef102317" href="/z/d/graphic/102317.html" rel="external">
          picture 1A
         </a>
         ) or as red, red-brownish, or hypopigmented plaques or tinea versicolor-like lesions mostly distributed on the trunk, neck, and face (
         <a class="graphic graphic_picture graphicRef102288 graphicRef130683" href="/z/d/graphic/102288.html" rel="external">
          picture 1B-C
         </a>
         ). Some patients may present verruca-like papillomatous lesions or seborrheic keratosis-like lesions [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
         Data on the clinical course of EV lesions are lacking. In the author's experience, the clinical phenotype of a specific skin area may change, and spontaneous regression or progression may occur.
        </p>
        <p>
         Patients with EV are not reported to have an increased susceptibility to infection from human papillomavirus (HPV) types causing cutaneous warts; anogenital warts; or cervical, anal, or penile cancer. In this regard, EV can be distinguished from other T cell, natural killer (NK) cell, and combined immunodeficiencies, such as that found in GATA2 deficiency, that are associated with recurrent mucocutaneous warts and HPV-related cancers [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4029.html" rel="external">
          "Cutaneous warts (common, plantar, and flat warts)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">
          "Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">
          "Virology of human papillomavirus infections and the link to cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H288191">
         <span class="h2">
          Skin cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately two-thirds of patients with EV develop actinic keratoses and cutaneous squamous cell carcinoma (SCC), including Bowen-type carcinoma in situ, at an early age, usually in the second or third decade of life [
         <a href="#rid56">
          56,57
         </a>
         ]. There is no known relationship between EV phenotypes and risk of skin cancer. (See
         <a class="medical medical_review" href="/z/d/html/5337.html" rel="external">
          "Cutaneous squamous cell carcinoma: Epidemiology and risk factors", section on 'Human papillomavirus infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H59702091">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of EV is suspected in a patient with a history of multiple diffuse, flat, wart-like skin lesions beginning in infancy or early childhood. The definitive diagnosis requires a skin biopsy and is based upon the histologic finding of hyperkeratosis, mild acanthosis, and vacuolated cells in the upper epidermis and demonstration of human papillomavirus (HPV) in the skin lesion. HPV DNA testing is performed in specialized laboratories. (See
         <a class="local">
          'Histopathology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8314.html" rel="external">
          "Human papillomavirus infections: Epidemiology and disease associations", section on 'Detection of HPV'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3298932536">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical mutational analysis is available for mutations in
         <em>
          TMC6
         </em>
         and
         <em>
          TMC8
         </em>
         genes and may be useful for patients suspected to have an inherited form of EV. Mutations can be identified in approximately 75 percent of patients with EV.
        </p>
        <p class="headingAnchor" id="H3972525734">
         <span class="h1">
          PRENATAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In families with a known diagnosis of EV and molecularly confirmed mutations, DNA testing can be performed on chorionic villus-derived cells or amniocytes from the pregnant mother. Early referral for genetics consultation prior to pregnancy and planning of pregnancies are recommended for carrier parents of an affected child if they are interested in prenatal diagnosis.
        </p>
        <p class="headingAnchor" id="H619572303">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of EV includes generalized verrucosis in the setting of primary immunodeficiencies, the acquired form of EV associated with secondary immunodeficiencies, and other skin conditions that can mimic EV clinically:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Generalized verrucosis associated with primary immunodeficiencies
         </strong>
         – Disseminated and/or recalcitrant mucocutaneous warts and human papillomavirus (HPV)-related cancers may occur in persons with T cell and/or natural killer (NK) cell primary immunodeficiencies, including severe and milder forms of combined immunodeficiency and NK cell deficiency syndromes [
         <a href="#rid38">
          38
         </a>
         ]. In contrast to patients with EV, patients with impaired cell-mediated immunity have increased susceptibility to infections with non-EV-HPV types and other common viruses, as well as with opportunistic, infectious agents. (See
         <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">
          "Severe combined immunodeficiency (SCID): An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">
          "Combined immunodeficiencies: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3949.html" rel="external">
          "NK cell deficiency syndromes: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="local">
          'Immune system abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare, congenital disorder characterized by neutropenia associated with hypogammaglobulinemia and increased susceptibility to warts and bacterial infections. (See
         <a class="local">
          'WHIM syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired epidermodysplasia verruciformis associated with secondary immunodeficiencies
         </strong>
         – An EV-like phenotype has been described in patients with defective cell-mediated immunity, predominantly in solid organ transplant recipients and patients with HIV infection. Patients with acquired EV have an increased risk of developing infections with non-EV-HPV and related cancers. (See
         <a class="local">
          'Acquired epidermodysplasia verruciformis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disseminated, flat warts
         </strong>
         – Flat warts (verrucae planae) are minimally elevated, flat-topped, skin-colored papules caused by HPV types 3, 10, and 28, commonly occurring on the face, neck, and legs (
         <a class="graphic graphic_picture graphicRef72086 graphicRef51139" href="/z/d/graphic/72086.html" rel="external">
          picture 3A-B
         </a>
         ). They are histologically indistinguishable from EV lesions. In contrast to EV, flat warts may disappear spontaneously in months to years. (See
         <a class="medical medical_review" href="/z/d/html/4029.html" rel="external">
          "Cutaneous warts (common, plantar, and flat warts)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical mimickers of epidermodysplasia verruciformis
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Confluent and reticulated papillomatosis of Gougerot and Carteaud
         </strong>
         – Confluent and reticulated papillomatosis of Gougerot and Carteaud is an uncommon cutaneous disorder of unknown etiology usually occurring in young adults [
         <a href="#rid58">
          58
         </a>
         ]. It presents with hyperpigmented, scaly patches with a reticulated appearance on the chest and upper back (
         <a class="graphic graphic_picture graphicRef67566 graphicRef76296 graphicRef54172 graphicRef66671" href="/z/d/graphic/67566.html" rel="external">
          picture 4A-D
         </a>
         ). Histology shows hyperkeratosis, acanthosis, and papillomatosis; HPV is absent. (See
         <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">
          "Acquired hyperpigmentation disorders", section on 'Confluent and reticulated papillomatosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tinea versicolor
         </strong>
         – Tinea versicolor is a common superficial fungal infection presenting with hypopigmented, hyperpigmented, or erythematous macules on the trunk and proximal upper extremities (
         <a class="graphic graphic_picture graphicRef52438" href="/z/d/graphic/52438.html" rel="external">
          picture 5
         </a>
         and
         <a class="graphic graphic_picture graphicRef59533" href="/z/d/graphic/59533.html" rel="external">
          picture 6
         </a>
         ). A potassium hydroxide (KOH) preparation showing both hyphae and yeast cells confirms the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/4039.html" rel="external">
          "Tinea versicolor (pityriasis versicolor)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Disseminated superficial porokeratosis
         </strong>
         – Disseminated superficial porokeratosis (DSAP) is a disorder of keratinization characterized by small erythematous, skin-colored, or hyperpigmented macules with a fine peripheral keratotic ridge (
         <a class="graphic graphic_picture graphicRef59742 graphicRef81874 graphicRef80248" href="/z/d/graphic/59742.html" rel="external">
          picture 7A-C
         </a>
         ). Histology shows the pathognomonic cornoid lamella, a thin column of tightly packed parakeratotic cells. (See
         <a class="medical medical_review" href="/z/d/html/13721.html" rel="external">
          "Porokeratosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Darier disease
         </strong>
         – Darier disease is an uncommon genodermatosis characterized by a persistent eruption of greasy, hyperkeratotic papules in seborrheic areas, such as forehead, scalp, chest, and back (
         <a class="graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef86186 graphicRef86187 graphicRef86188" href="/z/d/graphic/70000.html" rel="external">
          picture 8A-E
         </a>
         ). Some patients may have warty, flat-topped papules on the dorsa of the hands and feet that are clinically indistinguishable from similar lesions occurring in EV. The histologic finding of acantholysis and dyskeratosis can clarify the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">
          "Darier disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H619572315">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no curative therapies for EV. Systemic retinoids, including
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         and
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         , have been used in a few patients with transient benefit [
         <a href="#rid59">
          59-62
         </a>
         ]. Treatment of EV lesions with topical
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         has been reported in a few patients with inconsistent results [
         <a href="#rid22">
          22,63-66
         </a>
         ]. There are isolated reports of successful use of photodynamic therapy [
         <a href="#rid67">
          67
         </a>
         ] and topical
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [
         <a href="#rid60">
          60
         </a>
         ]. Recurrence is usual when treatment is discontinued. High-dose oral
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         has been used in a few patients with inconsistent results [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p>
         Patients should be educated to adopt strict sun protection measures to prevent the development of actinic keratoses and nonmelanoma skin cancer. (See
         <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">
          "Selection of sunscreen and sun-protective measures"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3046138">
         <span class="h2">
          Squamous cell carcinoma management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cryotherapy is an appropriate first-line treatment for of actinic keratoses, Bowen's disease (cutaneous squamous cell carcinoma [SCC] in situ), and low-risk invasive cutaneous SCCs in patients with EV. Surgical excision is appropriate for both low-risk SCC and for SCC at increased risk of recurrence. (See
         <a class="medical medical_review" href="/z/d/html/5339.html" rel="external">
          "Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"
         </a>
         .)
        </p>
        <p>
         Treatment of SCC with radiotherapy in EV patients has been associated with aggressive tumor recurrence and should be avoided [
         <a href="#rid70">
          70,71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H59703432">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with EV should undergo lifelong regular skin examination for early diagnosis and treatment of precancerous skin lesions and skin cancer. Patients without malignant tumors should be seen annually by a dermatologist. More frequent skin examinations at three- to six-month intervals may be necessary for patients treated for invasive squamous cell carcinoma (SCC). Approximately 70 to 80 percent of recurrences or metastases of cutaneous SCC occur within two years after therapy, and approximately 95 percent occur within five years. (See
         <a class="medical medical_review" href="/z/d/html/13713.html" rel="external">
          "Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1530526875">
         <span class="h1">
          WHIM SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome (MIM #193670) is a rare primary immunodeficiency disorder caused, in most cases, by gain-of-function pathogenic variants in the CXC chemokine receptor 4 gene (
         <em>
          CXCR4
         </em>
         ; MIM #162643) [
         <a href="#rid72">
          72,73
         </a>
         ]. Although WHIM syndrome is an autosomal dominant disorder, approximately 50 percent of cases result from a de novo mutation in children of unaffected parents. CXCR4 is expressed by most leukocyte subtypes [
         <a href="#rid74">
          74
         </a>
         ]. Mutations in the
         <em>
          CXCR4
         </em>
         gene cause an enhanced leukocyte response to the CXCR4 ligand, CXCL12, and thereby disrupt B cell and T cell development and traffic signaling. One consequence, called myelokathexis (characteristic neutropenia due to increased apoptosis and retention of atypical, hypersegmented, mature neutrophils in the bone marrow) is the hallmark feature of WHIM syndrome. (See
         <a class="medical medical_review" href="/z/d/html/8381.html" rel="external">
          "Approach to the patient with neutrophilia", section on 'Causes of neutrophilia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">
          "Congenital neutropenia", section on 'GATA2 deficiency/MonoMAC syndrome'
         </a>
         .)
        </p>
        <p>
         Pathogenic variants in the
         <em>
          CXCR4
         </em>
         gene are not present in all patients with WHIM syndrome. In such patients, enhanced leukocyte responsiveness to CXCL12 may be due to defects that affect CXCR4 internalization and desensitization, such as the G protein-coupled receptor kinase 3 (GRK3) and arrestin beta 2 (ARRB2) [
         <a href="#rid72">
          72,75,76
         </a>
         ]. However, other than
         <em>
          CXCR4
         </em>
         variants, no other pathogenic variants have been identified so far in patients with WHIM syndrome. Some, but not all, newborns with WHIM syndrome are detected using expanded newborn screening for primary immunodeficiency disorders. One report describes low T cell receptor excision circle (TREC) levels in at least some newborns with WHIM syndrome [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         Due to immunodeficiency, affected persons have increased susceptibility to human papillomavirus (HPV), chronic verrucosis, and recurrent respiratory tract infections [
         <a href="#rid78">
          78-80
         </a>
         ]. Less commonly, lymphomas and HPV-associated malignancies, such as cervical cancer, have been reported [
         <a href="#rid81">
          81
         </a>
         ]. However, the phenotype is variable, and not all patients have hypogammaglobulinemia or increased susceptibility to HPV infections, for example [
         <a href="#rid82">
          82
         </a>
         ]. In a 2020 case series, only 5 of 24 patients had warts that were considered severe [
         <a href="#rid81">
          81
         </a>
         ]. Congenital heart disease, including tetralogy of Fallot, and renal anomalies affect some patients [
         <a href="#rid77">
          77,83
         </a>
         ]. Typically, patients present with recurrent, sinopulmonary, bacterial infections and recalcitrant, cutaneous warts. Affected children are at risk for hearing loss due to recurrent otitis media [
         <a href="#rid81">
          81
         </a>
         ], and viral bronchiolitis is common in the neonatal period [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         Leukopenia is a feature, primarily due to neutropenia, although moderate lymphopenia is also seen [
         <a href="#rid82">
          82
         </a>
         ]. Peripheral blood neutrophil counts are typically low (&lt;500 cells/microL) [
         <a href="#rid78">
          78,84
         </a>
         ]. However, severely reduced counts may be absent at the time of medical attention since neutrophil count rises with infection. Bone marrow biopsy is required for diagnosis and reveals myelokathexis (mature neutrophils and accumulation of senescent neutrophils). Levels of immunoglobulin G (IgG) and/or immunoglobulin A (IgA) may be below normal. Antibody responses to vaccines are usually normal, but immunity may decrease rapidly, with absent protective titers one year after vaccination [
         <a href="#rid82">
          82
         </a>
         ]. Peripheral blood lymphocytes generally function normally, but in vitro proliferative responses to mitogens and antigens may be impaired, and cutaneous anergy with delayed hypersensitivity skin testing may also be seen.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          Immune globulin
         </a>
         replacement therapy is effective for reducing bacterial infections in patients with WHIM syndrome [
         <a href="#rid78">
          78
         </a>
         ]. Therapy with granulocyte colony-stimulating factor (G-CSF) results in increases in peripheral blood neutrophils but not other cell lines [
         <a href="#rid78">
          78,81
         </a>
         ]. Some patients have been successfully treated with hematopoietic cell transplantation [
         <a href="#rid85">
          85,86
         </a>
         ]. A small case series suggests treatment with
         <a class="drug drug_general" data-topicid="9517" href="/z/d/drug information/9517.html" rel="external">
          plerixafor
         </a>
         , a CXCR4 antagonist and stem cell mobilizing agent, is effective in increasing circulating leukocytes, decreasing infection frequency, and reducing the size and number of some warts in patients also treated with
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         [
         <a href="#rid87">
          87-90
         </a>
         ]. Some patients also had improvement in anemia, thrombocytopenia, myelofibrosis, immunoglobulin levels off of replacement therapy, and HPV-associated tumors [
         <a href="#rid90">
          90
         </a>
         ]. Similarly, mavorixafor, a selective CXCR4 antagonist, was shown to decrease the yearly infection rate (from 4.63 events, 95% CI 3.3-6.3 in the 12 months prior to the trial to 2.27 events, 95% CI 1.4-3.5 on therapy) and reduce the number of cutaneous warts by an average of 75 percent in a phase 2, open-label study in eight adults with WHIM syndrome [
         <a href="#rid91">
          91
         </a>
         ]. Increased mobilization of neutrophils and lymphocytes was observed. No treatment-related serious adverse events were reported. (See
         <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">
          "Inborn errors of immunity (primary immunodeficiencies): Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">
          "Immune globulin therapy in inborn errors of immunity"
         </a>
         .)
        </p>
        <p>
         There is at least one report of spontaneous resolution of WHIM syndrome. In one female with WHIM syndrome, almost all of the clinical manifestations of the disease spontaneously resolved in her fourth decade of life [
         <a href="#rid92">
          92
         </a>
         ]. Her cure is thought to demonstrate chromothripsis, a genetic process that is gaining importance in cancer biology. Chromothripsis refers to an event that causes multiple double-strand DNA breaks and chromosome arrangements in somatic cells [
         <a href="#rid93">
          93
         </a>
         ]. This patient was shown to have deletion of the mutated
         <em>
          CXCR4
         </em>
         allele on one copy of chromosome 2 via chromothripsis in a myeloid hemopoietic stem cell. That precursor cell was then able to reconstitute the granulocyte and monocyte compartments but not lymphocytes. Prior to this spontaneous "auto-reconstitution" via chromothripsis, the subject had already passed on the disorder in typical autosomal dominant fashion to two of her three children.
        </p>
        <p class="headingAnchor" id="H3047030">
         <span class="h1">
          ACQUIRED EPIDERMODYSPLASIA VERRUCIFORMIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A late-onset, EV-like condition has been reported in patients with impaired cell-mediated immunity and termed "acquired epidermodysplasia verruciformis" [
         <a href="#rid39">
          39
         </a>
         ]. Most patients with acquired EV are solid organ transplant recipients or patients with HIV infection [
         <a href="#rid39">
          39,94-98
         </a>
         ].
        </p>
        <p>
         Acquired EV has also been reported in some patients with severe combined immunodeficiency (SCID) following hemopoietic stem-cell transplantation, probably due to residual immune deficiency [
         <a href="#rid99">
          99,100
         </a>
         ]. Contributing factors may include deficiency of interleukin 2 receptor gamma, abnormal downstream signaling in keratinocytes, and/or a failure to meaningfully reconstitute natural killer (NK) cell development [
         <a href="#rid101">
          101,102
         </a>
         ].
        </p>
        <p>
         There are single-case reports of EV occurring in patients with lepromatous leprosy [
         <a href="#rid103">
          103
         </a>
         ], Hodgkin lymphoma [
         <a href="#rid104">
          104
         </a>
         ], and systemic lupus erythematosus [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
         Patients with acquired EV lack homozygous or compound heterozygous pathogenic variants in the
         <em>
          TMC6
         </em>
         or
         <em>
          TMC8
         </em>
         genes. Single-nucleotide polymorphism (SNP) variations in
         <em>
          TMC
         </em>
         have been reported in HIV-infected patients but not in transplant patients, suggesting a possible modulator function of SNPs in the development of acquired EV [
         <a href="#rid95">
          95,96,106
         </a>
         ].
        </p>
        <p>
         The clinical and histopathologic manifestations of EV are similar in inherited and acquired EV. Patients with acquired EV may present with diffuse xerosis as well as individual or coalescent flat-topped or hyperkeratotic papules.
        </p>
        <p>
         Histologic examination of acquired EV lesions reveals the typical blue cells with pallor and a mild acanthosis similar to lesions of inherited EV. The demonstration of beta-human papillomavirus (HPV) types 5 and 8 (or others) in skin lesions confirms the diagnosis of acquired EV.
        </p>
        <p>
         For patients with acquired EV, treatments are directed at reducing the immunosuppression or treating the underlying primary disease. In patients with HIV-associated acquired EV, improvement in cell counts after institution of antiretroviral therapy is inconsistently associated with clearance of EV-like lesions [
         <a href="#rid107">
          107-110
         </a>
         ]. Management and monitoring of the skin lesions is similar to inherited EV.
        </p>
        <p class="headingAnchor" id="H151024507">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathogenesis
         </strong>
         – Epidermodysplasia verruciformis (EV) is a rare autosomal recessive skin disease characterized by an abnormally high susceptibility to infection with certain types of human papillomavirus (HPV) called EV-HPV and increased risk of nonmelanoma skin cancer. In some families, EV is associated with biallelic pathogenic variants in either
         <em>
          TMC6
         </em>
         or
         <em>
          TMC8
         </em>
         (also named
         <em>
          EVER1
         </em>
         and
         <em>
          EVER2
         </em>
         ) on chromosome 17q25.3. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – During early infancy or childhood, individuals with EV usually develop flat-topped, papular lesions similar to verrucae planae on the extremities (
         <a class="graphic graphic_picture graphicRef102317" href="/z/d/graphic/102317.html" rel="external">
          picture 1A
         </a>
         ) or red-brownish plaques or tinea versicolor-like lesions on the trunk, neck, and face (
         <a class="graphic graphic_picture graphicRef102288" href="/z/d/graphic/102288.html" rel="external">
          picture 1B
         </a>
         ). (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of skin cancer
         </strong>
         – Approximately two-thirds of patients with EV develop actinic keratoses and cutaneous squamous cell carcinoma (SCC), including Bowen-type carcinoma in situ, at an early age, usually in the second or third decade of life. (See
         <a class="local">
          'Skin cancer'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of EV requires a skin biopsy and is based upon the histologic features and demonstration of HPV in a skin lesion. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8314.html" rel="external">
          "Human papillomavirus infections: Epidemiology and disease associations", section on 'Detection of HPV'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          WHIM syndrome
         </strong>
         – WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome typically includes increased susceptibility to HPV and chronic verrucosis as well as recurrent, sinopulmonary, bacterial infections. Potential treatment options include
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         replacement therapy, granulocyte colony-stimulating factor (G-CSF), and hematopoietic cell transplantation. Reports describe that patients with WHIM syndrome due to pathogenic variants in the CXC chemokine receptor 4 gene (
         <em>
          CXCR4
         </em>
         ) may respond to CXCR4 antagonist treatment. (See
         <a class="local">
          'WHIM syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired epidermodysplasia verruciformis
         </strong>
         – A late-onset form of EV termed "acquired epidermodysplasia verruciformis" has been reported in patients with impaired cell-mediated immunity, such as solid organ transplant recipients or patients with HIV infection. (See
         <a class="local">
          'Acquired epidermodysplasia verruciformis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – There are no curative therapies for EV. Systemic retinoids have been used with transient benefit in a few patients. Patients should be educated to adopt strict sun protection measures to prevent the development of nonmelanoma skin cancer. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance for skin cancer
         </strong>
         – Patients with EV should undergo lifelong regular skin examination for early diagnosis and treatment of precancerous skin lesions and skin cancer. (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1485588558">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Peter Itin, MD, and Bettina Burger, DSc, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lewandowsky F, Lutz W. [A case of a previously undescribed skin disease (epidermodysplasia verruciformis)]. Arch Dermatol Syph 1922; 141:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           JABLONSKA S, MILEWSKI B. [Information on epidermodysplasia verruciformis Lewandowsky-Lutz; positive results of auto- and heteroinoculation]. Dermatologica 1957; 115:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orth G, Jablonska S, Favre M, et al. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci U S A 1978; 75:1537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burger B, Itin PH. Epidermodysplasia verruciformis. Curr Probl Dermatol 2014; 45:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zahir A, Craig L, Rady P, et al. Epidermodysplasia verruciformis associated with HPV 10. Dermatol Online J 2013; 19:2.
          </a>
         </li>
         <li class="breakAll">
          Myers DJ, Fillman EP. Epidermodysplasia verruciformis. In: StatPearls, StatPearls Publishing, Treasure Island (FL) 2019.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howley PM, Pfister HJ. Beta genus papillomaviruses and skin cancer. Virology 2015; 479-480:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutzner MA. Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer 1978; 65:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majewski S, Jabłońska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajagopalan K, Bahru J, Loo DS, et al. Familial epidermodysplasia verruciformis of Lewandowsky and Lutz. Arch Dermatol 1972; 105:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quint KD, Genders RE, de Koning MN, et al. Human Beta-papillomavirus infection and keratinocyte carcinomas. J Pathol 2015; 235:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imahorn E, Yüksel Z, Spoerri I, et al. Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease. J Eur Acad Dermatol Venereol 2017; 31:1722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramoz N, Rueda LA, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32:579.
          </a>
         </li>
         <li class="breakAll">
          Orth G. Epidermodysplasia verruciformis. In: The Papovaviridae: The Papillomaviruses, 1st ed, Salzman NP, Howley PM (Eds), Plenum Press, 1987. Vol 2, p.199.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Androphy EJ, Dvoretzky I, Lowy DR. X-linked inheritance of epidermodysplasia verruciformis. Genetic and virologic studies of a kindred. Arch Dermatol 1985; 121:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott DF, Gammon B, Snijders PJ, et al. Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol 2009; 26:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tate G, Suzuki T, Kishimoto K, Mitsuya T. Novel mutations of EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. J Hum Genet 2004; 49:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun XK, Chen JF, Xu AE. A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis. Clin Exp Dermatol 2005; 30:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuo YG, Ma D, Zhang Y, et al. Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis. J Dermatol Sci 2006; 44:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gober MD, Rady PL, He Q, et al. Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol 2007; 127:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aochi S, Nakanishi G, Suzuki N, et al. A novel homozygous mutation of the EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. Br J Dermatol 2007; 157:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berthelot C, Dickerson MC, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007; 56:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rady PL, De Oliveira WR, He Q, et al. Novel homozygous nonsense TMC8 mutation detected in patients with epidermodysplasia verruciformis from a Brazilian family. Br J Dermatol 2007; 157:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarczyk M, Pons C, Mendoza JA, et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008; 205:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landini MM, Zavattaro E, Borgogna C, et al. Lack of EVER2 protein in two epidermodysplasia verruciformis patients with skin cancer presenting previously unreported homozygous genetic deletions in the EVER2 gene. J Invest Dermatol 2012; 132:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sunohara M, Ozawa T, Morimoto K, et al. Dye laser photodynamic therapy for Bowen's disease in a patient with epidermodysplasia verruciformis. Osaka City Med J 2012; 58:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizuno Y, Kato G, Shu E, et al. Merkel cell polyomavirus-positive Merkel cell carcinoma in a patient with epidermodysplasia verruciformis. Acta Derm Venereol 2015; 95:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youssefian L, Vahidnezhad H, Mahmoudi H, et al. Epidermodysplasia Verruciformis: Genetic Heterogeneity and EVER1 and EVER2 Mutations Revealed by Genome-Wide Analysis. J Invest Dermatol 2019; 139:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jong SJ, Créquer A, Matos I, et al. The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity to β-papillomaviruses. J Exp Med 2018; 215:2289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Przybyszewska J, Zlotogorski A, Ramot Y. Re-evaluation of epidermodysplasia verruciformis: Reconciling more than 90 years of debate. J Am Acad Dermatol 2017; 76:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurima K, Yang Y, Sorber K, Griffith AJ. Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis. Genomics 2003; 82:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarczyk M, Cassonnet P, Pons C, et al. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009; 73:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirianant L, Ousingsawat J, Tian Y, et al. TMC8 (EVER2) attenuates intracellular signaling by Zn2+ and Ca2+ and suppresses activation of Cl- currents. Cell Signal 2014; 26:2826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaud G, Guillemot D, Jacob Y, et al. EVER2 protein binds TRADD to promote TNF-α-induced apoptosis. Cell Death Dis 2013; 4:e499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majewski S, Hunzelmann N, Nischt R, et al. TGF beta-1 and TNF alpha expression in the epidermis of patients with epidermodysplasia verruciformis. J Invest Dermatol 1991; 97:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crequer A, Picard C, Pedergnana V, et al. EVER2 deficiency is associated with mild T-cell abnormalities. J Clin Immunol 2013; 33:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarczyk M, Dalard C, Hayder M, et al. EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation. PLoS One 2012; 7:e39995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang S, Wu JH, Lewis DJ, et al. A novel approach to the classification of epidermodysplasia verruciformis. Int J Dermatol 2018; 57:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers HD, Macgregor JL, Nord KM, et al. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009; 60:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobelli S, Laude H, Carlotti A, et al. Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy. Arch Dermatol 2011; 147:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limmer AL, Wu JH, Doan HQ, et al. Acquired epidermodysplasia verruciformis: a 10-year anniversary update. Br J Dermatol 2020; 182:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonsson A, Karanfilovska S, Lindqvist PG, Hansson BG. General acquisition of human papillomavirus infections of skin occurs in early infancy. J Clin Microbiol 2003; 41:2509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boxman IL, Mulder LH, Russell A, et al. Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals. Br J Dermatol 1999; 141:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitsuishi T, Ohara K, Suzuki T, et al. Epidermodysplasia verruciformis with keratoacanthoma, Bowen's disease and squamous cell carcinoma: isolation of high-risk types of HPV 5 and unknown type of human papillomavirus. J Eur Acad Dermatol Venereol 2008; 22:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horton JS, Stokes AJ. The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma. Oncoimmunology 2014; 3:e28288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghittoni R, Accardi R, Hasan U, et al. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010; 40:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akgül B, Lemme W, García-Escudero R, et al. UV-B irradiation stimulates the promoter activity of the high-risk, cutaneous human papillomavirus 5 and 8 in primary keratinocytes. Arch Virol 2005; 150:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dell'Oste V, Azzimonti B, De Andrea M, et al. High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J Invest Dermatol 2009; 129:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michael KM, Waterboer T, Pfister H, et al. Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. J Invest Dermatol 2010; 130:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol 2008; 321:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcelos AC, Sotto MN. Comparative analysis of the expression of cytokeratins (1, 10, 14, 16, 4), involucrin, filaggrin and e-cadherin in plane warts and epidermodysplasia verruciformis plane wart-type lesions. J Cutan Pathol 2009; 36:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westphal K, Akgül B, Storey A, Nindl I. Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures. Cell Oncol 2009; 31:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foong HB, Ibrahimi OA, Elpern DJ, et al. Multiple facial seborrheic keratosis-like lesions in a young woman with epidermodysplasia verruciformis. Int J Dermatol 2008; 47:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomasini C, Aloi F, Pippione M. Seborrheic keratosis-like lesions in epidermodysplasia verruciformis. J Cutan Pathol 1993; 20:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira WR, Festa Neto C, Rady PL, Tyring SK. Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol 2003; 17:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res 1997; 57:4214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang W, Ong G, Chong WS. Clinicopathological and diagnostic characterization of confluent and reticulate papillomatosis of Gougerot and Carteaud: a retrospective study in a South-East Asian population. Am J Clin Dermatol 2015; 16:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rallis E, Papatheodorou G, Bimpakis E, et al. Systemic low-dose isotretinoin maintains remission status in epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol 2008; 22:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vohra S, Sharma NL, Shanker V, et al. Autosomal dominant epidermodysplasia verruciformis: a clinicotherapeutic experience in two cases. Indian J Dermatol Venereol Leprol 2010; 76:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serarslan G, Balci DD, Homan S. Acitretin treatment in acrokeratosis verruciformis of Hopf. J Dermatolog Treat 2007; 18:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farro P, Zalaudek I, Ferrara G, et al. Unusual association between acrokeratosis verruciformis of Hopf and multiple keratoacanthomas. Successful therapy with acitretin. J Dtsch Dermatol Ges 2004; 2:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssen K, Lucker GP, Houwing RH, van Rijssel R. Epidermodysplasia verruciformis: unsuccessful therapeutic approach with imiquimod. Int J Dermatol 2007; 46 Suppl 3:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida R, Kato T, Kawase M, et al. Two sisters reveal autosomal recessive inheritance of epidermodysplasia verruciformis: a case report. BMC Dermatol 2014; 14:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nijhawan RI, Osei-Tutu A, Hugh JM. Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod. J Drugs Dermatol 2013; 12:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heratizadeh A, Völker B, Kupsch E, et al. [Successful symptomatic treatment of epidermodysplasia verruciformis with imiquimod 5% cream]. Hautarzt 2010; 61:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karrer S, Szeimies RM, Abels C, et al. Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1999; 140:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira WR, Neto CF, Rivitti EA. The lack of a clinical effect of cimetidine in the treatment of epidermodysplasia verruciformis. J Am Acad Dermatol 2004; 50:e14; author reply e15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Micali G, Nasca MR, Dall'Oglio F, Musumeci ML. Cimetidine therapy for epidermodysplasia verruciformis. J Am Acad Dermatol 2003; 48:S9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira WR, da Cruz Silva LL, Neto CF, Tyring S. Deleterious Effect of Radiation Therapy on Epidermodysplasia Verruciformis Patients. J Cutan Med Surg 2015; 19:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajabi MT, Ghasemi H, Safizadeh M, et al. Conjunctival squamous cell carcinoma with intraocular invasion after radiotherapy in epidermodysplasia verruciformis. Can J Ophthalmol 2014; 49:e43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai T, Malech HL. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol 2009; 16:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu Q, Chen H, Ojode T, et al. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood 2012; 120:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007; 1768:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagane B, Chow KY, Balabanian K, et al. CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 2008; 112:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balabanian K, Levoye A, Klemm L, et al. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest 2008; 118:1074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans MO 2nd, Petersen MM, Khojah A, et al. TREC Screening for WHIM Syndrome. J Clin Immunol 2021; 41:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetzler M, Talpaz M, Kleinerman ES, et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med 1990; 89:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003; 34:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol 2012; 130:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dale DC, Dick E, Kelley M, et al. Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome. Curr Opin Hematol 2020; 27:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tassone L, Notarangelo LD, Bonomi V, et al. Clinical and genetic diagnosis of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome in 10 patients. J Allergy Clin Immunol 2009; 123:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beaussant Cohen S, Fenneteau O, Plouvier E, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis 2012; 7:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hord JD, Whitlock JA, Gay JC, Lukens JN. Clinical features of myelokathexis and treatment with hematopoietic cytokines: a case report of two patients and review of the literature. J Pediatr Hematol Oncol 1997; 19:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moens L, Frans G, Bosch B, et al. Successful hematopoietic stem cell transplantation for myelofibrosis in an adult with warts-hypogammaglobulinemia-immunodeficiency-myelokathexis syndrome. J Allergy Clin Immunol 2016; 138:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kriván G, Erdos M, Kállay K, et al. Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome. Eur J Haematol 2010; 84:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011; 118:4957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dale DC, Bolyard AA, Kelley ML, et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood 2011; 118:4963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott DH, Liu Q, Velez D, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 2014; 123:2308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott DH, Pastrana DV, Calvo KR, et al. Plerixafor for the Treatment of WHIM Syndrome. N Engl J Med 2019; 380:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood 2020; 136:2994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott DH, Gao JL, Liu Q, et al. Chromothriptic cure of WHIM syndrome. Cell 2015; 160:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storchová Z, Kloosterman WP. The genomic characteristics and cellular origin of chromothripsis. Curr Opin Cell Biol 2016; 40:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunishige JH, Hymes SR, Madkan V, et al. Epidermodysplasia verruciformis in the setting of graft-versus-host disease. J Am Acad Dermatol 2007; 57:S78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohenstein E, Rady PL, Hergersberg M, et al. Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A--&gt;T polymorphism in the TMC8/EVER2 gene. Dermatology 2009; 218:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burger B, Kind F, Spoerri I, et al. HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6. AIDS 2010; 24:2758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison C, Eliezri Y, Magro C, Nuovo GJ. The histologic spectrum of epidermodysplasia verruciformis in transplant and AIDS patients. J Cutan Pathol 2002; 29:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendes AD, Bittencourt Mde J, Moure ER, et al. Acquired epidermodysplasia verruciformis in a renal transplant recipient--case report. An Bras Dermatol 2014; 89:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laffort C, Le Deist F, Favre M, et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 2004; 363:2051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowak K, Linzner D, Thrasher AJ, et al. Absence of γ-Chain in Keratinocytes Alters Chemokine Secretion, Resulting in Reduced Immune Cell Recruitment. J Invest Dermatol 2017; 137:2120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamili QUA, Seeborg FO, Saxena K, et al. Severe cutaneous human papillomavirus infection associated with natural killer cell deficiency following stem cell transplantation for severe combined immunodeficiency. J Allergy Clin Immunol 2014; 134:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abd Hamid IJ, Slatter MA, McKendrick F, et al. Long-term outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: a cohort report. Blood 2017; 129:2198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prestes-Carneiro LE, Nai GA, Silva MG, et al. Clinical presentation of tuberculoid leprosy in an epidermodysplasia verruciformis patient. J Infect Dev Ctries 2012; 6:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross G, Ellinger K, Roussaki A, et al. Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol 1988; 91:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes C, Chong AH, Tabrizi SN, et al. Epidermodysplasia verruciformis-like syndrome in association with systemic lupus erythematosus. Australas J Dermatol 2009; 50:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burger B, Spörri I, Stegmann DA, et al. Risk of Cutaneous Squamous Cell Carcinoma Development in Renal Transplant Recipients Is Independent of TMC/EVER Alterations. Dermatology 2015; 231:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas N, Fuchs PG, Hermes B, Henz BM. Remission of epidermodysplasia verruciformis-like skin eruption after highly active antiretroviral therapy in a human immunodeficiency virus-positive patient. Br J Dermatol 2001; 145:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lecapitaine AL, Perronne V, Granier F. Remission of an epidermodysplasia verruciformis-like eruption in an HIV-positive man long after immune restoration. Eur J Dermatol 2015; 25:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rallis E, Paparizos V, Kyriakis K, Katsambas A. Treatment of epidermodysplasia verruciformis in human immunodeficiency virus-positive patients. J Eur Acad Dermatol Venereol 2009; 23:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carré D, Dompmartin A, Verdon R, et al. Epidermodysplasia verruciformis in a patient with HIV infection: no response to highly active antiretroviral therapy. Int J Dermatol 2003; 42:296.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15509 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : [A case of a previously undescribed skin disease (epidermodysplasia verruciformis)]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13461537" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : [Information on epidermodysplasia verruciformis Lewandowsky-Lutz; positive results of auto- and heteroinoculation].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/206906" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24643182" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24021362" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Epidermodysplasia verruciformis associated with HPV 10.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24021362" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Epidermodysplasia verruciformis associated with HPV 10.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25724416" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Beta genus papillomaviruses and skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/212144" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503577" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5009624" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Familial epidermodysplasia verruciformis of Lewandowsky and Lutz.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25131163" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Human Beta-papillomavirus infection and keratinocyte carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28646613" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12426567" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12426567" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2990354" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : X-linked inheritance of epidermodysplasia verruciformis. Genetic and virologic studies of a kindred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19706093" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15042430" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Novel mutations of EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16045695" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17008061" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17139267" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17916203" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A novel homozygous mutation of the EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17368633" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17711520" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Novel homozygous nonsense TMC8 mutation detected in patients with epidermodysplasia verruciformis from a Brazilian family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18158319" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22158547" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lack of EVER2 protein in two epidermodysplasia verruciformis patients with skin cancer presenting previously unreported homozygous genetic deletions in the EVER2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23610850" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Dye laser photodynamic therapy for Bowen's disease in a patient with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24710670" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Merkel cell polyomavirus-positive Merkel cell carcinoma in a patient with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30036492" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Epidermodysplasia Verruciformis: Genetic Heterogeneity and EVER1 and EVER2 Mutations Revealed by Genome-Wide Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30068544" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity toβ-papillomaviruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28196644" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Re-evaluation of epidermodysplasia verruciformis: Reconciling more than 90 years of debate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12906855" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487731" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25220380" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : TMC8 (EVER2) attenuates intracellular signaling by Zn2+ and Ca2+ and suppresses activation of Cl- currents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23429285" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : EVER2 protein binds TRADD to promote TNF-α-induced apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1919049" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : TGF beta-1 and TNF alpha expression in the epidermis of patients with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22903682" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : EVER2 deficiency is associated with mild T-cell abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22761942" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30156265" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A novel approach to the classification of epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19150275" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Acquired epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21242344" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31545504" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Acquired epidermodysplasia verruciformis: a 10-year anniversary update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12791874" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : General acquisition of human papillomavirus infections of skin occurs in early infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468795" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18266691" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Epidermodysplasia verruciformis with keratoacanthoma, Bowen's disease and squamous cell carcinoma: isolation of high-risk types of HPV 5 and unknown type of human papillomavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24800179" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19838783" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The biological properties of E6 and E7 oncoproteins from human papillomaviruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15654507" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : UV-B irradiation stimulates the promoter activity of the high-risk, cutaneous human papillomavirus 5 and 8 in primary keratinocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18923444" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19924140" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18727487" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19515043" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparative analysis of the expression of cytokeratins (1, 10, 14, 16, 4), involucrin, filaggrin and e-cadherin in plane warts and epidermodysplasia verruciformis plane wart-type lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19478389" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18412865" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Multiple facial seborrheic keratosis-like lesions in a young woman with epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8396161" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Seborrheic keratosis-like lesions in epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24227816" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12834447" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinical aspects of epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9331078" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25589050" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinicopathological and diagnostic characterization of confluent and reticulate papillomatosis of Gougerot and Carteaud: a retrospective study in a South-East Asian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18363932" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Systemic low-dose isotretinoin maintains remission status in epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20826999" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Autosomal dominant epidermodysplasia verruciformis: a clinicotherapeutic experience in two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17520472" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Acitretin treatment in acrokeratosis verruciformis of Hopf.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16281601" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Unusual association between acrokeratosis verruciformis of Hopf and multiple keratoacanthomas. Successful therapy with acitretin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17973891" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Epidermodysplasia verruciformis: unsuccessful therapeutic approach with imiquimod.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25048734" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Two sisters reveal autosomal recessive inheritance of epidermodysplasia verruciformis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23545921" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20824263" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : [Successful symptomatic treatment of epidermodysplasia verruciformis with imiquimod 5% cream].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10354037" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15153919" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The lack of a clinical effect of cimetidine in the treatment of epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12582373" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Cimetidine therapy for epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26156649" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Deleterious Effect of Radiation Therapy on Epidermodysplasia Verruciformis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24767238" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Conjunctival squamous cell carcinoma with intraocular invasion after radiotherapy in epidermodysplasia verruciformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19057201" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : WHIM syndrome: congenital immune deficiency disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22596258" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17169327" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Regulation of CXCR4 signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18436740" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18274673" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33415666" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : TREC Screening for WHIM Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2239986" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12692554" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23036745" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Warts and all: human papillomavirus in primary immunodeficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31652152" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19321197" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical and genetic diagnosis of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome in 10 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23009155" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329467" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Clinical features of myelokathexis and treatment with hematopoietic cytokines: a case report of two patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27484033" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Successful hematopoietic stem cell transplantation for myelofibrosis in an adult with warts-hypogammaglobulinemia-immunodeficiency-myelokathexis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19878273" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21890643" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21835955" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24523241" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30625055" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Plerixafor for the Treatment of WHIM Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32870250" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25662009" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Chromothriptic cure of WHIM syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27023493" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The genomic characteristics and cellular origin of chromothripsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17938030" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Epidermodysplasia verruciformis in the setting of graft-versus-host disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19005244" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A--&gt;T polymorphism in the TMC8/EVER2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20980872" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12207742" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : The histologic spectrum of epidermodysplasia verruciformis in transplant and AIDS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24626660" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Acquired epidermodysplasia verruciformis in a renal transplant recipient--case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15207958" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28634034" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Absence ofγ-Chain in Keratinocytes Alters Chemokine Secretion, Resulting in Reduced Immune Cell Recruitment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25159470" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Severe cutaneous human papillomavirus infection associated with natural killer cell deficiency following stem cell transplantation for severe combined immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28209722" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Long-term outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: a cohort report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22711134" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Clinical presentation of tuberculoid leprosy in an epidermodysplasia verruciformis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2838553" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19178492" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Epidermodysplasia verruciformis-like syndrome in association with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26227733" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Risk of Cutaneous Squamous Cell Carcinoma Development in Renal Transplant Recipients Is Independent of TMC/EVER Alterations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11703302" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Remission of epidermodysplasia verruciformis-like skin eruption after highly active antiretroviral therapy in a human immunodeficiency virus-positive patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26243233" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Remission of an epidermodysplasia verruciformis-like eruption in an HIV-positive man long after immune restoration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18462300" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Treatment of epidermodysplasia verruciformis in human immunodeficiency virus-positive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12694498" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Epidermodysplasia verruciformis in a patient with HIV infection: no response to highly active antiretroviral therapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
